Puttarin Kulchaitanaroaj1, John M Brooks, Nathorn Chaiyakunapruk, Amber M Goedken, Elizabeth A Chrischilles, Barry L Carter. 1. aDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, Iowa, USA bHealth Economics Research Group (HERG), Department of Life Sciences, College of Health and Life Sciences, Brunel University London, Uxbridge, United Kingdom cDepartment of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA dSchool of Pharmacy, Monash University Malaysia, Subang Jaya, Selangor, Malaysia eCenter of Pharmaceutical Outcomes Research (CPOR), Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand fSchool of Pharmacy, University of Wisconsin, Madison, Wisconsin, USA gSchool of Population Health, University of Queensland, Brisbane, Queensland, Australia hDepartment of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa, USA.
Abstract
OBJECTIVE: To estimate long-term costs and outcomes attributable to a physician-pharmacist collaborative intervention compared with physician management alone for treating essential hypertension. METHODS: A Markov model cohort simulation with a 6-month cycle length to predict acute coronary syndrome, stroke, and heart failure throughout lifetime was performed. A cohort of 399 patients was obtained from two prospective, cluster randomized controlled clinical trials implementing physician-pharmacist collaborative interventions in community-based medical offices in the Midwest, USA. Framingham risk equations and other algorithms were used to predict the vascular diseases. SBP reduction due to the interventions deteriorated until 5 years. Direct medical costs using a payer perspective were adjusted to 2015 dollar value, and the main outcome was quality-adjusted life years (QALYs); both were discounted at 3%. The intervention costs were estimated from the trials, whereas the remaining parameters were from published studies. A series of sensitivity analyses including changing patient risks of vascular diseases, probabilistic sensitivity analysis, and a cost-effectiveness acceptability curve were performed. RESULTS: The lifetime incremental costs were $26 807.83 per QALY (QALYs gained = 0.14). The intervention provided the greatest benefit for the high-risk patients, moderate benefit for the trial patients, and the lowest benefit for the low-risk patients. If a payer is willing to pay $50 000 per QALY gained, in 48.6% of the time the intervention would be cost-effective. CONCLUSION: Team-based care such as a physician-pharmacist collaboration appears to be a cost-effective strategy for treating hypertension. The intervention is most cost-effective for high-risk patients.
OBJECTIVE: To estimate long-term costs and outcomes attributable to a physician-pharmacist collaborative intervention compared with physician management alone for treating essential hypertension. METHODS: A Markov model cohort simulation with a 6-month cycle length to predict acute coronary syndrome, stroke, and heart failure throughout lifetime was performed. A cohort of 399 patients was obtained from two prospective, cluster randomized controlled clinical trials implementing physician-pharmacist collaborative interventions in community-based medical offices in the Midwest, USA. Framingham risk equations and other algorithms were used to predict the vascular diseases. SBP reduction due to the interventions deteriorated until 5 years. Direct medical costs using a payer perspective were adjusted to 2015 dollar value, and the main outcome was quality-adjusted life years (QALYs); both were discounted at 3%. The intervention costs were estimated from the trials, whereas the remaining parameters were from published studies. A series of sensitivity analyses including changing patient risks of vascular diseases, probabilistic sensitivity analysis, and a cost-effectiveness acceptability curve were performed. RESULTS: The lifetime incremental costs were $26 807.83 per QALY (QALYs gained = 0.14). The intervention provided the greatest benefit for the high-risk patients, moderate benefit for the trial patients, and the lowest benefit for the low-risk patients. If a payer is willing to pay $50 000 per QALY gained, in 48.6% of the time the intervention would be cost-effective. CONCLUSION: Team-based care such as a physician-pharmacist collaboration appears to be a cost-effective strategy for treating hypertension. The intervention is most cost-effective for high-risk patients.
Authors: Catherine G Derington; Jordan B King; Kelsey B Bryant; Blake T McGee; Andrew E Moran; William S Weintraub; Brandon K Bellows; Adam P Bress Journal: Curr Hypertens Rep Date: 2019-11-07 Impact factor: 5.369
Authors: Katherine T Mills; Katherine M Obst; Wei Shen; Sandra Molina; Hui-Jie Zhang; Hua He; Lisa A Cooper; Jiang He Journal: Ann Intern Med Date: 2017-12-26 Impact factor: 25.391
Authors: Ana I Sanchez-Molina; Shalom I Benrimoj; Ramon Ferri-Garcia; Fernando Martinez-Martinez; Miguel Angel Gastelurrutia; Victoria Garcia-Cardenas Journal: BMC Health Serv Res Date: 2022-05-14 Impact factor: 2.908
Authors: Verughese Jacob; Jeffrey A Reynolds; Sajal K Chattopadhyay; David P Hopkins; Nicole L Therrien; Christopher D Jones; Jeffrey M Durthaler; Kimberly J Rask; Alison E Cuellar; John M Clymer; Thomas E Kottke Journal: Am J Prev Med Date: 2021-12-04 Impact factor: 5.043
Authors: Matthieu Lavielle; Déborah Puyraimond-Zemmour; Xavier Romand; Laure Gossec; Eric Senbel; Sophie Pouplin; Catherine Beauvais; Loriane Gutermann; Maryse Mezieres; Maxime Dougados; Anna Molto Journal: RMD Open Date: 2018-07-27